Revenue detailsIntegra LifeSciences Holdings logged revenue of $203.5 million. The 11 analysts polled by S&P Capital IQ foresaw a top line of $203.1 million on the same basis. GAAP reported sales were 4.8% higher than the prior-year quarter's $194.1 million.

EPS detailsNon-GAAP EPS came in at $0.48. The nine earnings estimates compiled by S&P Capital IQ forecast $0.55 per share on the same basis. GAAP EPS of $0.16 for Q4 were 75% lower than the prior-year quarter's $0.63 per share.

Looking aheadNext quarter's average estimate for revenue is $195.5 million. On the bottom line, the average EPS estimate is $0.58.

Next year's average estimate for revenue is $837.5 million. The average EPS estimate is $2.66.

Investor sentimentThe stock has a five-star rating (out of five) at Motley Fool CAPS, with 155 members out of 167 rating the stock outperform, and 12 members rating it underperform. Among 64 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 60 give Integra LifeSciences Holdings a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $42.69.

The health-care investing landscape is littered with also-rans and a few major winners. Is Integra LifeSciences Holdings performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.